文献速递气道管理术前评估与围术期医学

腹部手术快速序贯诱导实践与结局:多中心观察性队列研究

Rapid Sequence Induction Practices and Outcomes in Abdominal Surgery Patients: A Multicenter Observational Cohort Study.
PubMed 文献 · Anesthesiology · 2026-06-08

该多中心观察性队列研究利用MPOG数据库分析2015至2022年成人腹部手术的快速序贯诱导(RSI)实践,共纳入13家机构82,772例,其中9,352例(11.3%)记录为RSI。最常见的神经肌肉阻滞剂为琥珀胆碱(70.5%),但其使用比例从2015年的85.4%显著降至2022年的37.3%(P<0.0001),被罗库溴铵取代。罗库溴铵与琥珀胆碱相比,30天死亡率、诱导后低氧、肺部并发症及急性肾损伤风险无显著差异。

要点

  • 腹部手术RSI中琥珀胆碱使用比例从2015年85.4%降至2022年37.3%(P<0.0001)。
  • 罗库溴铵与琥珀胆碱相比,30天死亡率、低氧、肺部并发症及AKI风险无显著差异。
  • RSI病例视频喉镜使用率(16.2%)高于非RSI病例(8.0%)(P<0.0001)。

核心结论

  • 在美国多中心中,罗库溴铵在RSI中的使用逐渐增加并最终超过琥珀胆碱。
  • 罗库溴铵与琥珀胆碱相比,30天死亡率、低氧、肺部并发症及AKI风险无显著差异。

研究设计与样本

  • 多中心观察性队列研究,利用Multicenter Perioperative Outcomes Group数据库。
  • 纳入2015至2022年成人腹部手术患者,共13家机构82,772例,其中9,352例(11.3%)记录为RSI。

主要发现

  • 最常见的神经肌肉阻滞剂为琥珀胆碱(70.5%),但其使用比例从2015年85.4%显著降至2022年37.3%(P<0.0001),被罗库溴铵取代。
  • 患者通常接受多种镇静药联合给药。
  • 视频喉镜在RSI病例中的使用率为16.2%,非RSI病例为8.0%(P<0.0001)。
  • 罗库溴铵与琥珀胆碱相比,30天死亡率相对风险0.85(95%CI 0.67-1.09),低氧相对风险1.04(95%CI 0.61-1.77),肺部并发症相对风险0.93(95%CI 0.81-1.06),AKI相对风险1.05(95%CI 0.84-1.31)。

关键数值与推荐

  • RSI定义依据文档记录,在82,772例腹部手术中9,352例(11.3%)为RSI。
  • 主要终点为30天死亡率,次要终点包括诱导后低氧、肺部并发症和急性肾损伤(AKI)。
  • 罗库溴铵与琥珀胆碱相比,30天死亡率相对风险0.85(95%CI 0.67-1.09)。
  • 罗库溴铵与琥珀胆碱相比,低氧相对风险1.04(95%CI 0.61-1.77)。
  • 罗库溴铵与琥珀胆碱相比,肺部并发症相对风险0.93(95%CI 0.81-1.06)和AKI相对风险1.05(95%CI 0.84-1.31)。

临床怎么用

  • 在腹部手术RSI中,罗库溴铵可替代琥珀胆碱用于快速气道建立,两者在所研究的结局上无显著差异。
  • 临床选择神经肌肉阻滞剂时,可结合药物可获得性、禁忌证及患者因素,而不必仅基于所研究的结局差异。
  • 视频喉镜在RSI中应用较非RSI更常见,可考虑用于快速序贯诱导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rapid sequence induction (RSI) is commonly performed in the operating room to quickly secure the airway and minimize aspiration risk, especially in patients undergoing abdominal surgery. Current practice patterns of medications and RSI techniques used by anesthesiologists are not well described. METHODS: This observational cohort study utilized the Multicenter Perioperative Outcomes Group database to evaluate RSI practices on adult patients undergoing abdominal surgery from 2015 to 2022. The primary aim was to describe modern RSI practices. The authors evaluated peri-induction medication use and intubation techniques. The authors hypothesized that over time, rocuronium would become the most utilized agent. Additionally, the authors investigated how the choice of neuromuscular blocking agent affected outcomes using mixed-effects models and targeted maximum likelihood estimation. The primary endpoint was 30-day mortality. Secondary endpoints included postinduction hypoxia, pulmonary complications, and acute kidney injury (AKI). RESULTS: Across 13 institutions and 82,772 cases, 9,352 (11.3%) had a documented RSI. The most common neuromuscular blocking agent was succinylcholine (70.5%). However, the use of succinylcholine significantly decreased during the study period (85.4% of RSI cases in 2015, 37.3% in 2022; P < 0.0001), replaced by rocuronium. Patients usually received coadministration of multiple sedatives. Video laryngoscopy was more frequently used (16.2% of RSI vs. 8.0% of non-RSI cases; P < 0.0001). Rocuronium was not associated with a different risk of mortality (relative risk, 0.85; 95% CI, 0.67 to 1.09), hypoxia (relative risk, 1.04; 95% CI, 0.61 to 1.77), pulmonary complications (relative risk, 0.93; 95% CI, 0.81 to 1.06), or AKI (relative risk, 1.05; 95% CI, 0.84 to 1.31) as compared to succinylcholine. CONCLUSIONS: Across institutions in the United States, rocuronium has been increasingly used for RSI, eventually overtaking succinylcholine. Rocuronium use was not associated with a different risk of mortality, hypoxia, pulmonary complications, or AKI.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Marcus SG, Mathis M, Bokoch MP, et al. Rapid Sequence Induction Practices and Outcomes in Abdominal Surgery Patients: A Multicenter Observational Cohort Study. Anesthesiology. 2026. PMID: 42257652. doi:10.1097/ALN.0000000000006165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。